Seeking Alpha

Impax Labs (IPXL -11%) takes a hit on the back of the FDA's approval of Actavis' generic version...

Impax Labs (IPXL -11%) takes a hit on the back of the FDA's approval of Actavis' generic version of Shire's Adderall XR. Jefferies says the approval means an immediate hit to FY12 - 14 revenue and lowers its price target from $21 to $20.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|